Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Receivables (2017 - 2019)

Cogent Biosciences has reported Receivables over the past 3 years, most recently at $2.0 million for Q4 2019.

  • Quarterly results put Receivables at $2.0 million for Q4 2019, up 19.9% from a year ago — trailing twelve months through Dec 2019 was $2.0 million (up 19.9% YoY), and the annual figure for FY2019 was $2.0 million, up 19.9%.
  • Receivables for Q4 2019 was $2.0 million at Cogent Biosciences, up from $880000.0 in the prior quarter.
  • Over the last five years, Receivables for COGT hit a ceiling of $2.0 million in Q1 2019 and a floor of $830000.0 in Q4 2017.
  • Median Receivables over the past 3 years was $1.5 million (2019), compared with a mean of $1.5 million.
  • Biggest five-year swings in Receivables: soared 100.96% in 2018 and later plummeted 37.98% in 2019.
  • Cogent Biosciences' Receivables stood at $830000.0 in 2017, then soared by 100.96% to $1.7 million in 2018, then increased by 19.9% to $2.0 million in 2019.
  • The last three reported values for Receivables were $2.0 million (Q4 2019), $880000.0 (Q3 2019), and $1.5 million (Q2 2019) per Business Quant data.